KIF18B promotes tumor progression through activating the Wnt/β-catenin pathway in cervical cancer. 2018

Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People's Republic of China.

BACKGROUND KIF18B was identified as a potential oncogene by analysis of The Cancer Genome Atlas database. METHODS We assessed KIF18B expression and explored its clinical significance in cervical cancer tissues. We have also evaluated the effects of KIF18B on cervical cancer cell proliferation, migration, and invasion both in vitro and in vivo. RESULTS Our results show that KIF18B is overexpressed in cervical cancer tissues and is associated with a large primary tumor size, an advanced FIGO stage, and an advanced tumor grade. Knockdown of KIF18B induces cell cycle G1-phase arrest and inhibits the proliferation, migration, and invasion of cervical cancer cells, whereas its overexpression promotes proliferation, migration, and invasion in these cells. Moreover, silencing of KIF18B reduces expression of CyclinD1, β-catenin, C-myc, and p-GSK3β expression. CONCLUSIONS These data suggest that KIF18B can serve as a novel oncogene that promotes the tumorigenicity of cervical cancer cells by activating Wnt/β-catenin signaling pathway.

UI MeSH Term Description Entries

Related Publications

Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
October 2020, Journal of cellular physiology,
Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
May 2020, Cancer biology & medicine,
Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
March 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
September 2020, Oncology letters,
Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
November 2018, Journal of cellular biochemistry,
Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
January 2023, American journal of cancer research,
Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
June 2021, Cancer cell international,
Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
October 2020, Experimental cell research,
Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
January 2021, Open medicine (Warsaw, Poland),
Yaqin Wu, and Anpeng Wang, and Biqing Zhu, and Jian Huang, and Emei Lu, and Hanzi Xu, and Wenjie Xia, and Gaochao Dong, and Feng Jiang, and Lin Xu
May 2016, Oncotarget,
Copied contents to your clipboard!